Stock listing

Mesoblast Limited

Selected listing: LWB · SWB · EUR · DE

Mesoblast Limited (Stuttgart:LWB), Health Technology. Latest release Sep 24, 2026: FDA Approves New Potency Assay for Commercial Ryoncil.

LWB:SWBEURDEUpdated October 2, 2026

Ticker: Stuttgart:LWB
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Stuttgart
Currency: EUR

About Mesoblast Limited

Mesoblast Limited (Ticker: MSB) is a public company based in Australia, focused on developing innovative cell-based therapies. Mesoblast's research and development efforts aim to advance treatments for conditions such as heart disease and orthopedic disorders.

Latest news from Mesoblast Limited

FDA Approves New Potency Assay for Commercial Ryoncil

September 23, 2026

Mesoblast : Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)

August 27, 2026

Mesoblast Reports Substantial Revenue Growth to US$120M

August 26, 2026

Major Milestone Treatment Completed in P3 Trial for CLBP

August 16, 2026

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

July 28, 2026

All Mesoblast Limited news →

Events

Replays

Mesoblast Limited (MESO) Q4 2026 Earnings Call
Wed, Aug 26, 2026 · 06:30 PM ET
Watch
Mesoblast Limited (MESO) Q2 2026 Earnings Call
Thu, Feb 26, 2026 · 05:00 PM ET
Watch
Mesoblast Limited (MESO) Q4 2025 Earnings Call
Thu, Aug 28, 2025 · 06:30 PM ET
Watch

Research Mesoblast Limited

Mesoblast Limited company profile

View the public company page for Mesoblast Limited on 6ix.

Mesoblast Limited news

Read company news and market updates connected to Mesoblast Limited.

Mesoblast Limited investor events

Find investor webinars, events, and replay context for Mesoblast Limited.